E-Mail
IMAGE: The global brain signal in Alzheimer s disease patients is associated with weaker cerebrospinal fluid flow as compared with healthy controls view more
Credit: Feng Han and Xiao Liu @ The Pennsylvania State University
Evidence of sleep-dependent low-frequency (PLOS Biology by Xiao Liu and colleagues at The Pennsylvania State University. This neuronal activity was more strongly linked with cerebrospinal fluid flow in healthy controls than higher risk groups and patients, and the findings could serve as a potential imaging marker for clinicians in evaluating patients.
The development of Alzheimer s disease is believed to be driven by the buildup of the toxic proteins amyloid-β and tau in the brain. The brain s glymphatic system plays a crucial role in clearing these toxins and previous work has shown a possible relationship between sleep-dependent global brain activity and the glymphatic system by showing this activity is coupled by cerebrospinal fluid f
Hackensack Meridian
Health, New Jersey’s largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a research collaboration agreement that initially aims to help address the significant unmet needs of people living with Alzheimer’s disease, especially those experiencing the earliest stages of the disease, known as Mild Cognitive Impairment.
“We are proud to join forces with Eisai in our quest to expand early Alzheimer’s disease detection and improve community services for patients, caregivers and families impacted by the disease and other types of dementia,” said Robert C. Garrett, FACHE, CEO, Hackensack Meridian
Planning & Executing Small-Scale Model Qualification For Upstream & Downstream Biopharma Processing
By Joschka Johannes Buyel (Bayer AG), Klaus Kaiser (Bayer AG), Kiran Andra (Alexion), Robert G. Luo (GlaxoSmithKline R&D), Alexis Henry (Biogen), Caroline Leveder (Sanofi R&D), Mark Richards (Eisai Inc.), Trish Connolly (BioPhorum Development Group)
This article is the second in a three-part series that summarizes the discussions and exchanges of a BioPhorum Development Group workstream on small-scale model justification. Their purpose is to provide reference documents for bioprocess professionals who will carry out small-scale model justification. In order to write the articles, surveys were conducted among BioPhorum workstream team members on the practices of conducting small-scale model justification. The results of the surveys are not presented in these articles but are available in an expanded BioPhorum white paper on the topic. Part 1 discussed the applications, including viral